| scholarly article | Q13442814 |
| P2093 | author name string | Sue Hammond | |
| Paul T Martin | |||
| Karen Fernandez | |||
| Laura T Martin | |||
| Yelda Serinagaoglu | |||
| P2860 | cites work | Neural regulation of alpha-dystroglycan biosynthesis and glycosylation in skeletal muscle | Q73315875 |
| WW and EF hand domains of dystrophin-family proteins mediate dystroglycan binding | Q73419259 | ||
| Reduced expression of dystroglycan in breast and prostate cancer | Q74421326 | ||
| Duchenne muscular dystrophy-rhabdomyosarcoma, ichthyosis vulgaris/acute monoblastic leukemia: association of rare genetic disorders and childhood malignant diseases | Q74457281 | ||
| Cooperation of oncogenic K-ras and p53 deficiency in pleomorphic rhabdomyosarcoma development in adult mice | Q79755825 | ||
| Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations | Q81780679 | ||
| Tyrosine phosphorylation of beta-dystroglycan at its WW domain binding motif, PPxY, recruits SH2 domain containing proteins | Q24291934 | ||
| Tumor suppressor function of laminin-binding alpha-dystroglycan requires a distinct beta3-N-acetylglucosaminyltransferase | Q24312078 | ||
| Dystroglycan, a scaffold for the ERK-MAP kinase cascade | Q24537140 | ||
| Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method | Q25938999 | ||
| p53, the cellular gatekeeper for growth and division | Q27860990 | ||
| PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group | Q28201860 | ||
| Rapsyn may function as a link between the acetylcholine receptor and the agrin-binding dystrophin-associated glycoprotein complex | Q28293857 | ||
| Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix | Q28296676 | ||
| The sarcoglycan complex in the six autosomal recessive limb-girdle muscular dystrophies | Q28299653 | ||
| SH3 domain-mediated interaction of dystroglycan and Grb2 | Q28301162 | ||
| Association of dystrophin-related protein with dystrophin-associated proteins in mdx mouse muscle | Q28510608 | ||
| Evidence that dystroglycan is associated with dynamin and regulates endocytosis | Q28569266 | ||
| Mice with disrupted GM2/GD2 synthase gene lack complex gangliosides but exhibit only subtle defects in their nervous system | Q28587493 | ||
| Pax7 is required for the specification of myogenic satellite cells | Q28593927 | ||
| Membrane organization of the dystrophin-glycoprotein complex | Q29615149 | ||
| Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database | Q29616468 | ||
| Dystrophin: the protein product of the Duchenne muscular dystrophy locus | Q29618077 | ||
| PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma | Q30437251 | ||
| N-glycolylneuraminic acid deficiency in mice: implications for human biology and evolution | Q30500850 | ||
| Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells | Q33289241 | ||
| Characteristics of skeletal muscle in mdx mutant mice | Q33644573 | ||
| Common musculoskeletal tumors of childhood and adolescence | Q33697882 | ||
| Genes, chromosomes, and rhabdomyosarcoma | Q33759651 | ||
| Altered expression of natively glycosylated alpha dystroglycan in pediatric solid tumors | Q33774186 | ||
| A role for dystroglycan in epithelial polarization: loss of function in breast tumor cells. | Q33962881 | ||
| Function and genetics of dystrophin and dystrophin-related proteins in muscle | Q34120764 | ||
| Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma | Q39910409 | ||
| Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF-2 expression is associated with translocation-negative tumors | Q39940514 | ||
| PAX3 and PAX3-FKHR promote rhabdomyosarcoma cell survival through downregulation of PTEN. | Q40161083 | ||
| Leukemia inhibitory factor: a newly identified metastatic factor in rhabdomyosarcomas | Q40164482 | ||
| Altered expression of alpha-dystroglycan subunit in human gliomas | Q40297790 | ||
| An immunohistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma: the Children's Oncology Group experience | Q40304584 | ||
| Analysis of dystroglycan regulation and functions in mouse mammary epithelial cells and implications for mammary tumorigenesis | Q40323008 | ||
| Dystrophin Dp71 expression is down-regulated during myogenesis: role of Sp1 and Sp3 on the Dp71 promoter activity | Q40490351 | ||
| Proteolytic enzymes and altered glycosylation modulate dystroglycan function in carcinoma cells. | Q40519860 | ||
| Aberrant expression, processing and degradation of dystroglycan in squamous cell carcinomas. | Q40519985 | ||
| Anomalous dystroglycan in carcinoma cell lines. | Q40842397 | ||
| P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines | Q40864851 | ||
| Dystrophin isoforms DP71 and DP427 have distinct roles in myogenic cells. | Q40981761 | ||
| Dystroglycan: an extracellular matrix receptor linked to the cytoskeleton. | Q41238978 | ||
| Molecular cloning of a murine N-acetylgalactosamine transferase cDNA that determines expression of the T lymphocyte-specific CT oligosaccharide differentiation antigen | Q41466937 | ||
| Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. | Q41628899 | ||
| Genetic modeling of Ras-induced human rhabdomyosarcoma | Q42154621 | ||
| Deficiency of merosin in dystrophic dy mice and genetic linkage of laminin M chain gene to dy locus | Q42501151 | ||
| Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies | Q42524150 | ||
| Analysis of the PTCH coding region in human rhabdomyosarcoma | Q42525365 | ||
| Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma | Q42811960 | ||
| Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome | Q44178518 | ||
| Levels of PTEN protein modulate Akt phosphorylation on serine 473, but not on threonine 308, in IGF-II-overexpressing rhabdomyosarcomas cells | Q44645813 | ||
| Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma | Q47733005 | ||
| Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. | Q51761621 | ||
| Dystroglycan in development and disease. | Q52532615 | ||
| Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. | Q52547784 | ||
| Inhibition of dystroglycan binding to laminin disrupts the PI3K/AKT pathway and survival signaling in muscle cells. | Q52548027 | ||
| Loss of suppressor-of-fused function promotes tumorigenesis. | Q53334228 | ||
| Tumor promotion by Mdm2 splice variants unable to bind p53. | Q53375325 | ||
| Prognostic significance of activated AKT expression in soft-tissue sarcoma. | Q53622266 | ||
| Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice | Q57003773 | ||
| Dystrophin glycoprotein complex dysfunction: A regulatory link between muscular dystrophy and cancer cachexia | Q58492188 | ||
| Loss of heterozygosity in three embryonal tumours suggests a common pathogenetic mechanism | Q59053447 | ||
| Immunohistochemical evaluation of dystrophin expression in small round cell tumors of childhood. | Q64930759 | ||
| The molecular basis of muscular dystrophy in the mdx mouse: a point mutation | Q69514522 | ||
| Duchenne muscular dystrophy and concomitant metastatic alveolar rhabdomyosarcoma | Q73273989 | ||
| Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma | Q34236278 | ||
| Pathologic classification of rhabdomyosarcomas and correlations with molecular studies | Q34250993 | ||
| Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma | Q34334974 | ||
| Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma | Q34341396 | ||
| Association of childhood rhabdomyosarcoma with neurofibromatosis type I and birth defects | Q34371040 | ||
| Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma | Q34405491 | ||
| Muscular dystrophies involving the dystrophin-glycoprotein complex: an overview of current mouse models. | Q34699458 | ||
| Alternative and aberrant splicing of MDM2 mRNA in human cancer | Q34768629 | ||
| Disruption of imprinted genes at chromosome region 11p15.5 in paediatric rhabdomyosarcoma | Q34786119 | ||
| A Drosophila model of the rhabdomyosarcoma initiator PAX7-FKHR. | Q35037288 | ||
| Dystrophin-glycoprotein complex: post-translational processing and dystroglycan function. | Q35056189 | ||
| Dystroglycan glycosylation and its role in matrix binding in skeletal muscle | Q35123507 | ||
| Defective muscle basement membrane and lack of M-laminin in the dystrophic dy/dy mouse | Q35493060 | ||
| Dystroglycan expression is frequently reduced in human breast and colon cancers and is associated with tumor progression. | Q35791328 | ||
| Dystroglycan complex in cancer | Q35837819 | ||
| Overexpression of the cytotoxic T cell (CT) carbohydrate inhibits muscular dystrophy in the dyW mouse model of congenital muscular dystrophy 1A. | Q35928246 | ||
| The dystroglycan complex: from biology to cancer | Q36141779 | ||
| A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. | Q36232550 | ||
| Progressive muscular dystrophy in alpha-sarcoglycan-deficient mice | Q36276730 | ||
| Dystroglycan: from biosynthesis to pathogenesis of human disease. | Q36367346 | ||
| Mice lacking complex gangliosides develop Wallerian degeneration and myelination defects | Q36399818 | ||
| Survivin: an inhibitor of apoptosis in pediatric cancer | Q36420774 | ||
| Nitric oxide-GAPDH-Siah: a novel cell death cascade | Q36457904 | ||
| Mechanisms of disease: congenital muscular dystrophies-glycosylation takes center stage | Q36577280 | ||
| PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound | Q36611142 | ||
| Rhabdomyosarcomas in adults and children: an update | Q36647274 | ||
| Survivin-directed RNA interference cocktail is a potent suppressor of tumour growth in vivo | Q36930279 | ||
| Loss of alpha-dystroglycan laminin binding in epithelium-derived cancers is caused by silencing of LARGE. | Q37160880 | ||
| Mdm2-mediated ubiquitylation: p53 and beyond. | Q37508606 | ||
| Pax3:Fkhr interferes with embryonic Pax3 and Pax7 function: implications for alveolar rhabdomyosarcoma cell of origin. | Q37598845 | ||
| Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. | Q37598848 | ||
| Hedgehog-independent overexpression of transforming growth factor-beta1 in rhabdomyosarcoma of Patched1 mutant mice | Q38300301 | ||
| Effects of RAS on the genesis of embryonal rhabdomyosarcoma. | Q38301662 | ||
| Plectin 1f scaffolding at the sarcolemma of dystrophic (mdx) muscle fibers through multiple interactions with beta-dystroglycan. | Q39734956 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | embryonal rhabdomyosarcoma | Q5370233 |
| P304 | page(s) | 416-434 | |
| P577 | publication date | 2009-12-17 | |
| P1433 | published in | The American Journal of Pathology | Q4744259 |
| P1476 | title | Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts | |
| P478 | volume | 176 |
| Q46456978 | A novel mouse model of rhabdomyosarcoma underscores the dichotomy of MDM2-ALT1 function in vivo |
| Q39278570 | ABC of multifaceted dystrophin glycoprotein complex (DGC). |
| Q37580831 | Advances in pediatric rhabdomyosarcoma characterization and disease model development |
| Q37595289 | Cancer-related genes in the transcription signature of facioscapulohumeral dystrophy myoblasts and myotubes |
| Q38893243 | Cavin-1 and Caveolin-1 are both required to support cell proliferation, migration and anchorage-independent cell growth in rhabdomyosarcoma |
| Q47630972 | Cytoskeleton and ECM tumor mutant peptides: Increased protease sensitivities and potential consequences for the HLA class I mutant epitope reservoir |
| Q33886594 | DNA damage, somatic aneuploidy, and malignant sarcoma susceptibility in muscular dystrophies |
| Q36167600 | Deletion of Galgt2 (B4Galnt2) reduces muscle growth in response to acute injury and increases muscle inflammation and pathology in dystrophin-deficient mice |
| Q39274601 | Dystroglycan function is a novel determinant of tumor growth and behavior in prostate cancer |
| Q36025454 | Dystrophin and dysferlin double mutant mice: a novel model for rhabdomyosarcoma |
| Q34479070 | Dystrophin is a tumor suppressor in human cancers with myogenic programs |
| Q64067092 | Exogenous expression of the glycosyltransferase LARGE1 restores α-dystroglycan matriglycan and laminin binding in rhabdomyosarcoma |
| Q48243281 | Facioscapulohumeral dystrophy myoblasts efficiently repair moderate levels of oxidative DNA damage |
| Q40678653 | Flat cells come full sphere: Are mutant cytoskeletal-related proteins oncoprotein-monsters or useful immunogens? |
| Q60300365 | Genomic analysis identifies frequent deletions of Dystrophin in olfactory neuroblastoma |
| Q38703661 | Identification of Sets of Cytoskeletal Related and Adhesion-related Coding Region Mutations in the TCGA Melanoma Dataset that Correlate with a Negative Outcome |
| Q47119855 | Increased FSHD region gene1 expression reduces in vitro cell migration, invasion, and angiogenesis, ex vivo supported by reduced expression in tumors. |
| Q36503375 | Induction of a regenerative microenvironment in skeletal muscle is sufficient to induce embryonal rhabdomyosarcoma in p53-deficient mice |
| Q98164936 | Low expression of ANT1 confers oncogenic properties to rhabdomyosarcoma tumor cells by modulating metabolism and death pathways |
| Q35667137 | MURC/cavin-4 Is Co-Expressed with Caveolin-3 in Rhabdomyosarcoma Tumors and Its Silencing Prevents Myogenic Differentiation in the Human Embryonal RD Cell Line |
| Q34023157 | Myostatin is elevated in congenital heart disease and after mechanical unloading |
| Q36142754 | Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems. |
| Q38105879 | Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma. |
| Q41116449 | Protected cytoskeletal-related proteins: Towards a resolution of contradictions regarding the role of the cytoskeleton in cancer |
| Q33997217 | Rhabdomyosarcomas in aging A/J mice |
| Q37973827 | Rhabdomyosarcomas: an overview on the experimental animal models. |
| Q47162190 | The human, F-actin-based cytoskeleton as a mutagen sensor |
| Q38831343 | Zebrafish Rhabdomyosarcoma |
Search more.